Biocare Hepaguard Forte Vegetable - Pack of 60 Capsules

FREE Shipping

Biocare Hepaguard Forte Vegetable - Pack of 60 Capsules

Biocare Hepaguard Forte Vegetable - Pack of 60 Capsules

RRP: £99
Price: £9.9
£9.9 FREE Shipping

In stock

We accept the following payment methods


We considered variations in subcategories, for example, different doses or durations of nutritional supplementation, as the same treatment node. This form of imputation can decrease the weight of the study for calculation of mean differences and may bias the effect estimate to no effect for calculation of standardised mean differences ( Higgins 2011b).

Ultrasound may yield false‐positive results in 7 out of 100 people without fatty liver disease ( Hernaez 2011). It is in no way intended that the reader uses any of the nutritional supplements sold on this web site before seeking professional advice or that these supplements be used in addition to or as a substitute for any previously prescribed medication without first consulting with the health professional that prescribed this medication. For network meta‐analysis, to identify the effect estimate of a comparison, say A vs B, look at the cell that occupies the row corresponding to intervention A and the column corresponding to intervention B for the effect estimate that is obtained directly (i. Various interventions have been used in attempts to treat people with NAFLD, including nutritional supplementation (probiotics, prebiotics, synbiotics, vitamin supplementation, polyunsaturated fatty acid supplementation) ( Nabavi 2014; Sharifi 2014; Li 2015; Nogueira 2016; Mofidi 2017); lifestyle modifications such as dietary changes and exercise training (not included in this review) ( Abenavoli 2015; Shojaee‐Moradie 2016; Zhang 2016; Houghton 2017); pharmacological interventions (not included in this review) ( Lombardi 2017); and weight reduction surgery (bariatric surgery) (not included in this review) for obese people with NAFLD ( Adorini 2012; Anstee 2012; Chalasani 2012; Paschos 2012; Abenavoli 2013). Reasons related to interventions or co‐interventions: Ersoz 2005; Zhang 2008; Khoshbaten 2010a; Akcam 2011; Dela Cruz 2012; Hajiaghamohammadi 2012; Basu 2014; Han 2014; Chambers 2018; Petyaev 2018; Mahmoudi 2020; Podszun 2020; {"type":"clinical-trial","attrs":{"text":"NCT00820651","term_id":"NCT00820651"}}NCT00820651.The codes that we used for analysis accounted for the correlation between effect sizes from studies with more than two groups. Non‐alcoholic fatty liver disease (NAFLD) is an accumulation of fat in the liver of people who have no history of significant alcohol consumption, use of medicines, disease such as hepatitis C virus infection, or other conditions such as starvation that can damage the liver. If it was not possible to calculate the standard deviation from the P value or from the confidence intervals, we planned to impute the standard deviation using the largest standard deviation in other trials for that outcome.

We summarised the population and methodological characteristics of trials included in the network meta‐analysis in a table based on pairwise comparisons.

We assessed inconsistency (statistical evidence of violation of the transitivity assumption) by fitting both an inconsistency model and a consistency model. We assessed the transitivity assumption by comparing the distribution of potential effect modifiers (clinical: presence of diabetes and NASH; methodological: risk of bias, year of randomisation, duration of follow‐up) across the different pairwise comparisons. As robust as the horse's body appears from the outside, environmental and stress loads can cause problems for the horse's organism.

For the random‐effects model, we used a prior distributed uniformly (limits: 0 to 5) for the between‐trial standard deviation parameter and assumed that this variability would be the same across treatment comparisons ( Dias 2016).We included randomised clinical trials with participants who have non‐alcohol‐related fatty liver disease (NAFLD), irrespective of method of diagnosis, age and diabetic status of participants, or presence of non‐alcoholic steatohepatitis (NASH). Accordingly, high‐quality randomised comparative clinical trials with adequate follow‐up are needed. This Review looked at people of any sex, age, and ethnic origin, with non‐alcohol‐related liver disease. A total of 52 trials (3372 participants) reported mortality at maximal follow‐up of 2 to 28 months ( Wang 2008; Gomez 2009; Sanyal 2010; Vajro 2011; Malaguarnera 2012; Illnait 2013; Magosso 2013; Nobili 2013; Shavakhi 2013; Wong 2013a; Chachay 2014; Foroughi 2014; Sanyal 2014; Scorletti 2014; Somi 2014; Aller 2015; Bae 2015; Chen 2015a; Dasarathy 2015; Zhang 2015; Ferolla 2016; Heeboll 2016; Li 2016; Nabavi 2016; Yari 2016; Chan 2017; Famouri 2017a; Hussain 2017; Manzhalii 2017; Sakpal 2017; Schattenberg 2017; Shahmohammadi 2017; Bakhshimoghaddam 2018; Eriksson 2018; Kobyliak 2018; Lewis 2018; Oscarsson 2018; Taghvaei 2018; Zamani 2018; Bril 2019; Cheraghpour 2019; Duseja 2019; Jazayeri‐Tehrani 2019; Abhari 2020; Afzali 2020; Boonyagard 2020; Mansour 2020; Poparn 2020; Scorletti 2020; Yari 2020; Soleimani 2021; EUCTR 2008‐008275‐34‐GB). If we identified any cross‐over randomised clinical trials, we planned to include only outcomes after the period of the first intervention because included treatments could have residual effects, provided the period of follow‐up before the cross‐over was sufficient to address the objectives of this review ( Higgins 2011b), noting that the period of follow‐up before the cross‐over to address the objectives of this review will be around eight years (we are not aware of any cross‐over trial with such a long period of follow‐up before the cross‐over).

  • Fruugo ID: 258392218-563234582
  • EAN: 764486781913
  • Sold by: Fruugo

Delivery & Returns


Address: UK
All products: Visit Fruugo Shop